ClinicalTrials.gg
RecruitingNCT06381063KETOPAINUpdated Jul 23, 2025

Non-steroidal Anti-inflammatory in Cardiac Surgery

A Phase 3 interventional study of pain management and ketoprofen in Acute Postoperative Pain, Non-steroidal Anti-inflammatory Drugs and Cardiac Surgery, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Centre Hospitalier Universitaire, Amiens · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Pain, Postoperative with a site in France — 18 open to participants now, 21 under way, 3 of them phase 3. Pain, Postoperative · France.

Planned enrollment
22nd of 83
238 · median 140
Started
2024
with 5 others
Phase 3
19 of 103
3 open now
Primary completion
2027-03
later than 6 of 20 live
Registered
84th of 103
by date
Lead sponsor
8 of 103
Centre Hospitalier Universitaire, Amiens

Among the 103 studies in Pain, Postoperative with a site in France, this one is the 22nd largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2024, is one of 19 in phase 3, reaches primary completion later than 6 of the 20 other live ones, and was the 84th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

18 of the 103 studies in Pain, Postoperative with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Pain, Postoperative with a site in France, or all of them as a file.
02

Study summary

Non-steroidal anti-inflammatory drugs (NSAID) are part the multimodal strategy in pain management after surgery. However, major concerns are raised in cardiac surgery given the potential side effects of NSAID with more bleeding and acute kidney injury. The investigators hypothesized that NSAID are safe in the early postoperative course after cardiac surgery with respect to contraindication.

03

Conditions studied

  • Acute Postoperative Pain
  • Non-steroidal Anti-inflammatory Drugs
  • Cardiac Surgery
  • Pain Intensity
  • Multimodal Pain Management

Keywords

  • Acute Postoperative Pain
  • non-steroidal anti-inflammatory drugs
  • cardiac surgery
  • pain intensity
  • multimodal pain management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • scheduled for cardiac surgery (aortic valve replacement, coronary artery bypass graft, mitral valve repair or replacement, intracardiac tumor, aortic root repair)
  • under cardiopulmonary bypass
  • Affiliation to the French national healthcare system
  • Written consent obtained

Exclusion criteria

Exclusion Criteria:

  • age\<18
  • weight\<50 kg
  • chronic use of NSAID
  • mini-invasive surgery
  • NSAID
  • NSAID allergy
  • Nefopam contraindication
  • Paracetamol contraindication
  • Tramadol contraindication
  • Urgent surgery
  • Endocarditis
  • drug
  • infection with CD4\<200 mm3
  • Organ transplantation
  • Stage 4 or 5 chronic kidney disease
  • Gastro duodenal ulcer
  • Pregnancy
  • Depression
  • Auto immune disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
238 participants (estimated)

Study arms

  • Experimental
    Ketoprofen

    Ketoprofen 100 mg twice a day, during 48 after surgery, intravenous administration

    Drug: pain management · Drug: ketoprofen

  • Placebo comparator
    Placebo

    Placebo twice a day, during 48 h after surgery, intravenous administration

    Drug: pain management · Drug: PLacebo

Interventions

  • Drugpain management

    o Pain management in both arms Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day, patient control analgesia with morphine or oxycontin

  • Ketoprofen 100 mg twice a day, during 48 after surgery, intravenous administration

  • DrugPLacebo

    Placebo twice a day, during 48 h after surgery, intravenous administration

06

What researchers measure

Primary outcomes

  1. reduction in pain intensity during chest physiotherapy at 24 hours from the end of surgery

    Pain intensity will be assessed using the NRS at 24 hours from the end of surgery during chest physiotherapy

    Time frame: at 24 hours

  2. NSAIDs reduce postoperative at rest at 24 hours from the end of surgery

    Pain intensity will be assessed at rest at 24 hours from the end surgery using the numerous rating scale (NRS) graded from 1 (no pain) to 10 (high pain intensity)

    Time frame: at 24 hours

Secondary outcomes

  1. Change in pain trajectory during the first 7 days after cardiac surgery

    Pain trajectory will be assessed every day using NRS and trajectory will be defined as following

    Time frame: 7 days

  2. Change in cumulative opioid within 48 hours after surgery

    Total dose of oxynorm or morphine will be recorded from the end of surgery to 48 h after and expressed in milligram

    Time frame: 48 hours

  3. Change in pulmonary postoperative complications within 7 days after surgery

    Postoperative pulmonary complications will be defined by the occurrence of at least one item among following: atelectasis, pneumonia, acute respiratory distress syndrome, acute respiratory failure, bronchospasm

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Huette P, Moussa M, Diouf M, Lefebvre T, Bayart G, Guilbart M, Viart C, Haye G, Bar S, Caus T, Soriot-Thomas S, Boddaert S, Alshatri HY, Tarpin P, Fumery O, Beyls C, Dupont H, Mahjoub Y, Besnier E, Abou-Arab O. Effect of non-steroidal anti-inflammatory drugs on the management of postoperative pain after cardiac surgery: a multicenter, randomized, controlled, double-blind trial (KETOPAIN Study). Trials. 2024 Sep 16;25(1):613. doi: 10.1186/s13063-024-08326-z. PubMed 39285437 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2027, 36 months after the start.

Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 36 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2024
First posted
Apr 24, 2024
StartActual
Mar 27, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Jul 2027
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06381063
Responsible party
Sponsor
First posted
Apr 24, 2024
Start date
Mar 27, 2024
Primary completion
Mar 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 23, 2025

Study contacts

Osama ABOU ARAB, Pr
Contact
abouarab.osama@chu-amiens.fr
03 22 08 78 36

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion